The delivery of drugs to patients is one of the most crucial parts of the pharmaceutical industry. The specific method of drug delivery can have a major impact on the effectiveness and applicability ...
SAN FRANCISCO — A sirolimus-eluting balloon was found to be noninferior to conventional stenting in separate trials of patients undergoing percutaneous coronary interventions (PCIs), suggesting these ...
DENVER, CO — A drug-eluting balloon proved to be the match of a drug-eluting stent for treatment of any in-stent restenosis, offering the potential to spare patients from receiving yet another stent ...
Active pharmaceutical ingredients (APIs), including both small molecules and biologic compounds, are often encapsulated in microspheres and nanoparticles. This encapsulation is utilized for specific ...
SELUTION SLR™ Drug-Eluting Balloon (DEB) achieves amongst the highest reported patency for any drug-eluting or drug-coated technology at 3 years in the SELUTION SFA Japan Trial, with 81.5% primary ...
Dr. Mehran is a co-Principal Investigator of the breakthrough "SELUTION4ISR Trial," with results presented at Transcatheter Cardiovascular Therapeutics 2025. A new drug-eluting balloon can perform ...
Please provide your email address to receive an email when new articles are posted on . A sirolimus-eluting balloon was noninferior to drug-eluting stents in treating de novo coronary lesions. The ...
SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient ...
Impact of human immunodeficiency virus on hepatocellular carcinoma outcomes: A National Inpatient Sample. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback